Skip to content

Holger Wesche

Holger Wesche

Company: Harpoon Therapeutics Inc.

Job title: CSO


Dr. Wesche joined Harpoon Therapeutics with 20 years of biotech experience focused on target validation, drug discovery and drug development as well as multi-site project management in the fields of oncology and inflammation. His previous role was as scientific director at Amgen where he was responsible for cross-functional organization and coordination of the next generation BiTE platform, the industry’s leading T-cell engaging antibody platform. He also led several drug discovery projects through pre-clinical development. Dr. Wesche is co-author of numerous publications and several US patents. Dr. Wesche received his PhD, summa cum laude, in biochemistry and Immunology from the University of Hannover, Germany.


TriTACs – Development Challenges and Opportunities for Novel T Cell Engagers 9:00 am

• T cell engager background: work well in liquid tumors, limited success in solid tumors so far • Analysis of differences: targets space, tumor microenvironment, drug exposures • Considerations for target selection and platform design to address these challenges • Description of the TriTAC platform • End with an update on the lead program, HPN424,…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.